UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
Form
6-K
Report
of Foreign Private Issuer
Pursuant
to Rule 13a-16 or 15d-16
under
the Securities Exchange Act of 1934
For
the month of March 2026
Commission
file number: 001-42375
Polyrizon
Ltd.
(Translation
of registrant’s name into English)
5
Ha-Tidhar Street
Raanana,
4366507, Israel
(Address
of principal executive offices)
Indicate
by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form
20-F ☒ Form 40-F ☐
CONTENTS
Attached
hereto and incorporated herein is the Registrant’s press release issued on March 17, 2026, titled “Polyrizon Signs an Agreement
with Leading Global Preclinical CRO as Part of Clinical Development Program.”
The
first four paragraphs of the press release attached to this Report of Foreign Private Issuer on Form 6-K as Exhibit 99.1 are incorporated
by reference into the Registrant’s Registration Statements on Form S-8 (File No. 333-284410 and 333-288923)
and Form F-3 (333-291368),
filed with the Securities and Exchange Commission, to be a part thereof from the date on which this report is submitted, to the extent
not superseded by documents or reports subsequently filed or furnished.
EXHIBIT
INDEX
| Exhibit No. |
|
|
| 99.1 |
|
Press release titled: “Polyrizon Signs an Agreement with Leading Global Preclinical CRO as Part of Clinical Development Program” |
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned, thereunto duly authorized.
| |
Polyrizon
Ltd. |
| |
|
| Date:
March 17, 2026 |
By: |
/s/
Tomer Izraeli |
| |
Name: |
Tomer
Izraeli |
| |
Title: |
Chief
Executive Officer |
Exhibit 99.1
Polyrizon
Signs an Agreement with Leading Global Preclinical CRO as Part of Clinical Development Program
Raanana,
Israel, March 17, 2026 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (“Polyrizon” or the “Company”), a pre-clinical-stage
biotechnology company developing intranasal administrated solutions, today announced the signing of an agreement with a leading global
preclinical Contract Research Organization (CRO), a recognized expert in biocompatibility and regulatory-compliant testing.
This
agreement forms part of Polyrizon's ongoing efforts to advance its clinical development program, which also includes a recent manufacturing
of GMP production of clinical trial material, successful completion of an FDA pre-submission meeting, and positive preclinical data demonstrating
effective allergen-blocking performance.
Under
the agreement, the CRO will conduct a comprehensive package of preclinical biocompatibility studies in accordance with ISO 10993 standards
and GLP requirements. The studies are expected to commence in the second quarter of 2026 and represent a key milestone in Polyrizon’s
potential regulatory pathway toward initiating clinical trials, which are planned to commence later this year.
The
preclinical program includes cytotoxicity, sensitization, intracutaneous reactivity, acute systemic toxicity and pyrogenicity assessments,
designed to support regulatory submissions and ensure product safety prior to human studies.
“This
agreement marks an important step in the advancement of our development program,” said Tomer Izraeli, CEO of Polyrizon. “We
believe that engaging a globally recognized preclinical partner strengthens our regulatory strategy and supports our expected timeline
toward initiating clinical trials later this year.”
Polyrizon
continues to execute its development roadmap as it advances its proprietary nasal medical device technology platform toward clinical
validation.
About
Polyrizon
Polyrizon
is a development stage biotech company specializing in the development of innovative medical device hydrogels delivered in the form of
nasal sprays, which form a thin hydrogel-based shield containment barrier in the nasal cavity that can provide a barrier against viruses
and allergens from contacting the nasal epithelial tissue. Polyrizon’s proprietary Capture and Contain TM, or C&C, hydrogel
technology, comprised of a mixture of naturally occurring building blocks, is delivered in the form of nasal sprays, and potentially
functions as a “biological mask” with a thin shield containment barrier in the nasal cavity. Polyrizon are further developing
certain aspects of our C&C hydrogel technology such as the bioadhesion and prolonged retention at the nasal deposition site for intranasal
delivery of drugs. Polyrizon refers to its additional technology, which is in an earlier stage of pre-clinical development, that is focused
on nasal delivery of active pharmaceutical ingredients, or APIs, as Trap and Target ™, or T&T. For more information, please
visit https://polyrizon-biotech.com.
Forward
Looking Statements
This
press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of
1995 and other securities laws. Words such as “expects,” “anticipates,” “intends,” “plans,”
“believes,” “seeks,” “estimates” and similar expressions or variations of such words are intended
to identify forward-looking statements. For example, the Company is using forward-looking statements when it discusses ongoing efforts
to advance its clinical development program and the timing and progress of its clinical trials. Forward-looking statements are not historical
facts, and are based upon management’s current expectations, beliefs and projections, many of which, by their nature, are inherently
uncertain. Such expectations, beliefs and projections are expressed in good faith. However, there can be no assurance that management’s
expectations, beliefs and projections will be achieved, and actual results may differ materially from what is expressed in or indicated
by the forward-looking statements. Forward-looking statements are subject to risks and uncertainties that could cause actual performance
or results to differ materially from those expressed in the forward-looking statements. For a more detailed description of the risks
and uncertainties affecting the Company, reference is made to the Company’s reports filed from time to time with the Securities
and Exchange Commission (“SEC”), including, but not limited to, the risks detailed in the Company’s annual report filed
with the SEC on March 11, 2025 and subsequent filings with the SEC. Forward-looking statements speak only as of the date the statements
are made. The Company assumes no obligation to update forward-looking statements to reflect actual results, subsequent events or circumstances,
changes in assumptions or changes in other factors affecting forward-looking information except to the extent required by applicable
securities laws. If the Company does update one or more forward-looking statements, no inference should be drawn that the Company will
make additional updates with respect thereto or with respect to other forward-looking statements. References and links to websites have
been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release.
Polyrizon is not responsible for the contents of third-party websites.
Contacts:
Michal Efraty
Investor Relations
IR@polyrizon-biotech.com
